Salubris Biotherapeutics
Salubris Biotherapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the biologics JK06 and JK08 in melanoma, colorectal cancer, non-small-cell lung cancer, small-cell lung cancer and advanced solid tumours.
Overview
Salubris Biotherapeutics (SalubrisBio) is a clinical-stage biotechnology company founded in 2016 that discovers and develops antibody and protein-based biologics for cardiovascular disease and oncology. Its pipeline includes JK06, JK07 and JK08. It is the US subsidiary of Salubris Pharmaceuticals of Shenzhen. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06667960 (phase 1/2, Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer) and NCT05620134 (phase 1/2, Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- approved products +6
- phase 1/2 +1
- targets +4
- modalities +4
- regions +6
- 24-month regulatory events +6
- registry trials +30
JK08 is an experimental fusion protein or cytokine from Salubris Biotherapeutics in phase 2 trials for melanoma, colorectal cancer and non-small-cell lung cancer, aimed at CTLA-4.
Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.